NASDAQ:MBIO Mustang Bio (MBIO) Stock Price, News & Analysis → The Overlooked Retirement Asset You Probably Don’t Own (From Crypto 101 Media) (Ad) Free MBIO Stock Alerts $0.31 +0.01 (+3.31%) (As of 05/17/2024 ET) Add Compare Share Share Today's Range$0.31▼$0.3350-Day Range$0.24▼$1.1652-Week Range$0.22▼$8.17Volume184,277 shsAverage Volume213,687 shsMarket Capitalization$3.24 millionP/E RatioN/ADividend YieldN/APrice Target$11.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get Mustang Bio alerts: Email Address Mustang Bio MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside3,585.9% Upside$11.50 Price TargetShort InterestHealthy0.91% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.85Based on 13 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.93) to ($0.35) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.62 out of 5 stars 3.5 Analyst's Opinion Consensus RatingMustang Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageMustang Bio has only been the subject of 1 research reports in the past 90 days.Read more about Mustang Bio's stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.91% of the float of Mustang Bio has been sold short.Short Interest Ratio / Days to CoverMustang Bio has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Mustang Bio has recently decreased by 39.78%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldMustang Bio does not currently pay a dividend.Dividend GrowthMustang Bio does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for MBIO. Previous Next 2.7 News and Social Media Coverage News SentimentMustang Bio has a news sentiment score of 0.85. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.42 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 13 news articles for Mustang Bio this week, compared to 1 article on an average week.Search InterestOnly 3 people have searched for MBIO on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Mustang Bio insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.10% of the stock of Mustang Bio is held by insiders.Percentage Held by InstitutionsOnly 9.95% of the stock of Mustang Bio is held by institutions.Read more about Mustang Bio's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Mustang Bio are expected to grow in the coming year, from ($1.93) to ($0.35) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Mustang Bio is -0.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Mustang Bio is -0.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Mustang Bio's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad True Market Insidersget a piece of the profit from this land This isn’t the prettiest land on earth. But it might be the most valuable. And you don’t have to own, lease, or rent any land.Click here to see my #1 investment for 2024. About Mustang Bio Stock (NASDAQ:MBIO)Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develops MB-117 and MB-217, a gene therapy program for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. The company also develops MB-106 CAR T cell program for B cell non-hodgkin lymphoma and chronic lymphocytic leukemia; MB-101 CAR T cell program for glioblastoma; MB-108, a next-generation oncolytic herpes simplex virus. It has license agreements with Nationwide Children's Hospital, CSL Behring; Mayo Clinic; Leiden University Medical Centre; SIRION Biotech GmbH. The company was incorporated in 2015 and is headquartered in Worcester, Massachusetts.Read More MBIO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MBIO Stock News HeadlinesMay 16 at 12:15 PM | investorplace.comMBIO Stock Earnings: Mustang Bio Beats EPS for Q1 2024May 16 at 2:42 AM | americanbankingnews.comMustang Bio, Inc. (NASDAQ:MBIO) Expected to Post FY2024 Earnings of ($0.65) Per ShareMay 15, 2024 | americanbankingnews.comMustang Bio (NASDAQ:MBIO) Given New $2.00 Price Target at HC WainwrightMay 15, 2024 | americanbankingnews.comEquities Analysts Set Expectations for Mustang Bio, Inc.'s Q2 2024 Earnings (NASDAQ:MBIO)May 13, 2024 | markets.businessinsider.comMustang Bio Earns Buy Rating: Strong Financials and Promising Clinical DevelopmentsMay 11, 2024 | americanbankingnews.comShort Interest in Mustang Bio, Inc. (NASDAQ:MBIO) Declines By 39.8%May 2, 2024 | globenewswire.comMustang Bio Announces Closing of $4 Million Public OfferingApril 30, 2024 | msn.comLSD Microdosing For PMS? After Confirming Antidepressant Effects, Clinical Trials Will Assess If It Addresses Mood IssuesApril 29, 2024 | globenewswire.comMustang Bio Announces Pricing of $4 Million Public OfferingApril 22, 2024 | bizjournals.comWorcester biotech down to 11 employees after asset sale stallsApril 16, 2024 | bizjournals.comBiotech cites federal review of deal with Chinese firm in latest staff cutsApril 15, 2024 | msn.comMustang Bio stock tumbles 27% amid news of mass layoffsApril 14, 2024 | investing.comMustang Bio announces major workforce reductionApril 12, 2024 | marketwatch.comMustang Bio to Cut Global Headcount by 81%March 28, 2024 | globenewswire.comMustang Bio Announces Vision for CAR T-Cell Therapy Platform Expansion into Autoimmune DiseasesMarch 11, 2024 | globenewswire.comMustang Bio Reports Full-Year 2023 Financial Results and Recent Corporate HighlightsMarch 7, 2024 | tmcnet.comMustang Bio Announces Publication in Nature Medicine of Data from Phase 1 Trial Evaluating MB-101 IL13Ra2-targeted CAR T-Cells in High-Grade GliomaMarch 7, 2024 | markets.businessinsider.comWhy Rush Street Interactive Shares Are Trading Higher By Around 25%; Here Are 20 Stocks Moving PremarketMarch 7, 2024 | globenewswire.comMustang Bio Announces Publication in Nature Medicine of Data from Phase 1 Trial Evaluating MB-101 IL13Rα2-targeted CAR T-Cells in High-Grade GliomaFebruary 13, 2024 | uk.investing.comMustang Bio Inc (MBIO)January 11, 2024 | finance.yahoo.comMustang Bio to Participate in the B. Riley Securities 4th Annual Oncology ConferenceJanuary 6, 2024 | morningstar.comMustang Bio Inc MBIODecember 27, 2023 | benzinga.comMustang Bio Stock (NASDAQ:MBIO) Dividends: History, Yield and DatesDecember 22, 2023 | seekingalpha.comMBIO Mustang Bio, Inc.December 12, 2023 | msn.comMustang Bio files to sell 2.74M shares of common stock for holdersSee More Headlines Receive MBIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Mustang Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/11/2024Today5/19/2024Next Earnings (Estimated)8/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:MBIO CUSIPN/A CIK1680048 Webwww.mustangbio.com Phone(781) 652-4500FaxN/AEmployees80Year FoundedN/APrice Target and Rating Average Stock Price Target$11.50 High Stock Price Target$18.00 Low Stock Price Target$2.00 Potential Upside/Downside+3,585.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($4.40) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-51,600,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-1,243.22% Return on Assets-195.64% Debt Debt-to-Equity RatioN/A Current Ratio0.53 Quick Ratio0.74 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.48) per share Price / Book-0.65Miscellaneous Outstanding Shares10,390,000Free Float10,172,000Market Cap$3.24 million OptionableNot Optionable Beta1.75 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesMr. Michael S. Weiss Esq. (Age 58)Executive Chairman Comp: $60kDr. Manuel Litchman M.D. (Age 70)President, CEO & Director Comp: $480.79kMr. James B. Murphy (Age 67)Interim Chief Financial Officer Mr. Peter Carney (Age 37)Controller & Interim Chief Accounting Officer Mr. Matthew Wein J.D.VP & General CounselMs. Debra Manning SPHRSenior VP & Head of Human ResourcesMs. Lynn E. Bayless M.S.VP & Head of Regulatory AffairsDr. Bruce Dezube M.D.Senior VP & Head of Clinical DevelopmentMr. Greg Furrow M.S.Chief Quality OfficerMr. Richard Bodmer M.S.Head of CMC DevelopmentMore ExecutivesKey CompetitorsBiophytisNASDAQ:BPTSYBiophytisNASDAQ:BPTSCohBarNASDAQ:CWBRVirpax PharmaceuticalsNASDAQ:VRPXAraviveNASDAQ:ARAVView All Competitors MBIO Stock Analysis - Frequently Asked Questions Should I buy or sell Mustang Bio stock right now? 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Mustang Bio in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" MBIO shares. View MBIO analyst ratings or view top-rated stocks. What is Mustang Bio's stock price target for 2024? 3 equities research analysts have issued 12 month price objectives for Mustang Bio's stock. Their MBIO share price targets range from $2.00 to $18.00. On average, they predict the company's share price to reach $11.50 in the next year. This suggests a possible upside of 3,585.9% from the stock's current price. View analysts price targets for MBIO or view top-rated stocks among Wall Street analysts. How have MBIO shares performed in 2024? Mustang Bio's stock was trading at $1.35 at the start of the year. Since then, MBIO shares have decreased by 76.9% and is now trading at $0.3120. View the best growth stocks for 2024 here. When is Mustang Bio's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 12th 2024. View our MBIO earnings forecast. How were Mustang Bio's earnings last quarter? Mustang Bio, Inc. (NASDAQ:MBIO) posted its quarterly earnings results on Monday, March, 11th. The company reported ($0.71) earnings per share for the quarter, beating analysts' consensus estimates of ($1.68) by $0.97. When did Mustang Bio's stock split? Mustang Bio's stock reverse split on Tuesday, April 4th 2023. The 1-15 reverse split was announced on Tuesday, April 4th 2023. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, April 4th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. What other stocks do shareholders of Mustang Bio own? Based on aggregate information from My MarketBeat watchlists, some companies that other Mustang Bio investors own include OPKO Health (OPK), Sorrento Therapeutics (SRNE), CymaBay Therapeutics (CBAY), TG Therapeutics (TGTX), VBI Vaccines (VBIV), Fortress Biotech (FBIO), Viking Therapeutics (VKTX), Selecta Biosciences (SELB), Aytu BioPharma (AYTU) and Kadmon (KDMN). How do I buy shares of Mustang Bio? Shares of MBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:MBIO) was last updated on 5/19/2024 by MarketBeat.com Staff From Our PartnersBuy this small stock before coming AI Tidal WaveChaikin AnalyticsCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingShocking $16T Elon Musk Crypto LeakCrypto 101 MediaForget Bitcoin: This $8 Stock Is the Next Big ThingBehind the MarketsDems have chosen Biden replacement?Paradigm PressHow Biden has already won 2024Porter & CompanyExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersA letter is coming from the "Bureau of the Fiscal Service".Stansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mustang Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.